Matching articles for "Issue 1333"
Rosiglitazone (Avandia) Revisited
The Medical Letter on Drugs and Therapeutics • March 8, 2010; (Issue 1333)
The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19,...
The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).
Primary Prevention of Ulcers in Patients Taking Aspirin or NSAIDs
The Medical Letter on Drugs and Therapeutics • March 8, 2010; (Issue 1333)
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high...
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are common causes of peptic ulcer disease. Patients infected with Helicobacter pylori who take aspirin or another NSAID have an especially high risk. Drugs that have been tried for prevention of ulcers in patients taking NSAIDs including H2-receptor antagonists, proton pump inhibitors (PPIs), aluminum- or magnesium-containing antacids, the prostaglandin misoprostol (Cytotec, and others), and antibiotics to eradicate H. pylori.
Click here to view the free full article.
Click here to view the free full article.
Hyperbaric Oxygen Therapy for Refractory Wounds
The Medical Letter on Drugs and Therapeutics • March 8, 2010; (Issue 1333)
Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot...
Hyperbaric oxygen (HBO2) therapy, breathing 100% O2 while exposed to increased atmospheric pressure, has been used for years to treat refractory wounds, especially diabetic foot ulcers.
Addendum: Cost of Ustekinumab (Stelara)
The Medical Letter on Drugs and Therapeutics • March 8, 2010; (Issue 1333)
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg...
In the Medical Letter article on ustekinumab (Stelara) for psoriasis (2010; 52:7), footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.